Business Wire

KIRIN-HOLDINGS

20.5.2024 03:31:17 CEST | Business Wire | Press release

Share
Kirin Holdings will begin online sales of "Electric Salt Spoon", a spoon that uses electricity to enhance salty and umami taste*1, on May 20

Kirin Holdings Company, Limited (Kirin) will launch as a new business in the Health Science domain (Health Science business) a limited offering of 200 units of Electric Salt Spoon, which enhances the salty and umami taste of low-sodium foods with the power of electricity, on Monday, May 20, 2024 at its official online store (https://electricsalt.shop.kirin.co.jp/). In addition, a limited number of units will be available at Hands Inc. stores beginning in June.
This tableware-type device is equipped with technology that enhances the salty taste perceived when eating low-sodium foods by approximately 1.5 times*2,3. The technology was developed through joint research with the Meiji University Dr. Homei Miyashita Laboratory of the Department of Frontier Media Science, School of Interdisciplinary Mathematical Sciences (Miyashita Laboratory). Through this device, we aim to realize a society in which people can improve their lifestyle in a delicious way.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240519949395/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Target and current levels of salt intake (g/day) (Graphic: Business Wire)

1.

The 3rd Neurostimulation Interface Research Meeting. March 2023
"Influence on umami taste of the electric taste waveform that intensifies the saltiness of low-sodium foods"

2.

KIRIN news release on April 11, 2022 https://www.kirinholdings.com/jp/newsroom/release/2022/0411_01.html

3.

Change value of evaluation regarding saltiness intensity in a sample that imitates ordinary food and a sample with 30% less salt. Tested using chopsticks equipped with Electirc Salt technology (current 0.1~0.5 mA). Thirty-one men and women aged 40-65 years who are/were currently or have been reducing salt in the past were asked about the saltiness intensity they perceived when eating the test food, and 29 of the 31 respondents answered that the saltiness had increased.

The issue of "excessive salt intake" among Japanese people and dissatisfaction with the taste of low-sodium food
The daily salt intake of Japanese people aged 20 and over is 10.1g*4, which is much higher than the World Health Organization's (WHO) recommended salt intake of 5.0g*5. In addition, salt intake has not reached the "Healthy Japan 21 (2nd stage)*6 target for all age groups over 20 years old among both men and women*7. Target will be further lowered in the 3rd stage, making "excessive salt intake" the most important nutritional issue for Japanese people according to the Ministry of Health, Labor and Welfare.
In our questionnaire survey of persons who are currently eating a low-sodium diet or intend to do so*8, approximately 60% of the respondents felt issues exist in relation to low-sodium foods, and of those people, approximately 80% were dissatisfied with the taste. If low-sodium diets can be continued in better tasting way, it may lead to improvement in nutritional issues.

4.

Ministry of Health, Labour and Welfare National Health and Nutrition Survey 2019

5.

WHO Guidelines 2012

6.

Ministry of Health, Labour and Welfare Food Environment Strategy Initiative https://sustainable-nutrition.mhlw.go.jp/contents/sodium

7.

Ministry of Health, Labour and Welfare Basic Policy for the Comprehensive Promotion of the Health of the People
https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kenkounippon21_00006.html

8.

Target: Men and women aged 40-79 living in the Tokyo metropolitan area (N=4,411) Format: Web survey Approximately 47% of all respondents are eating a low-sodium diet or intend to do so.

"Electric Salt Spoon" addresses social issues and consumer needs
"Electric Salt Spoon" is a tableware-type device developed based on the concept of "a life with delicious food for all people to address social issues and consumer needs for low-sodium food taste.
In our survey*9, respondents who are trying to reduce salt consumption ranked ramen noodles in first place and miso soup in second place as the "foods they would like to eat with a strong taste instead of a thin taste. This indicates that there is a need to eat ramen with a strong taste as a "reward" for refraining from eating it due to their efforts to reduce salt intake, as well as a need to enjoy foods that are eaten on a daily basis, such as "soup," in a delicious way.
Directed at commercialization of Electric Salt, we have continued to develop tableware such as chopsticks and bowls, but we decided to first develop and market a "spoon" in consideration of the technical characteristics and the meals for which there are high consumer needs.

9.

Kirin Survey Period: January 2022 Target: 120 men and women aged 30~69 who are trying to reduce salt intake Format: CLT survey, multiple responses allowed. Press release regarding the results of this research (Monday, April 11, 2022) https://www.kirinholdings.com/jp/newsroom/release/2022/0411_01.html

Product Overview, Sales Method and Developer's Comments 

Product

Product name

Electric Salt Spoon

Dimensions

Approx. W250 x D38 x H25 (mm)

Weight

Approx. 60g (excluding batteries)

Power Supply

3V lithium battery (CR2)

Price

19,800 yen (tax included)

Features

A weak electric current is passed from the tip of the spoon to the food to enhance the taste of the meal*, including salty and umami taste. We have improved the technology so that the spoon can be used naturally at the dining table and designed the device with a focus on ease of use and durability.

* There are individual differences in experience. Also, the feeling may vary depending on the dish.

How to use

Turn the power on with the switch on the handle of the spoon, select the desired intensity (4 levels), and use the spoon as you would a regular spoon.

Details

https://electricsalt.shop.kirin.co.jp/electricsalt-spoon/product/ES-S001/

* There are certain conditions under which this product may not be used (e.g. minors and persons fitted with a pacemaker or other medical electrical device). Please check the "Safety Precautions" on the official online store or on the product box.

Recommendation

It can be used with soups with lots of ingredients, curry, fried rice, food in a bowl, ramen noodles, and other meals in general.

 
Sales Method

1. Official Online Store (https://electricsalt.shop.kirin.co.jp/)

Initial sales volume

200 units (planned)

* Please apply from the product purchase page on the official online store.

* If the number of applications exceeds the number of units to be sold, sales will be conducted by lottery.

Application Period

Monday, May 20, 2024 - Sunday, June 2, 2024

* In case of lottery sales, all applicants will be notified on Thursday, June 6.

Shipping Schedule

Mid-June 2024

* Sales are scheduled to continue after June. We will announce it on the official Electric Salt online store in due course.

2. Hands Inc

Start of sales

June 2024 (Planned)
* For more information, please refer to the website/ press release of Hands Inc.
(URL: https://shinjuku.hands.net/item/7f/7f-14.html)

Developer's Comments
Ai SATO Health Science Business Division, New Business Group
People trying to reduce salt intake often stated, "I understand the importance of reducing salt intake, but it is too hard for me to continue." This prompted us to start research and development of Electric Salt in 2019, which finally led to the marketing of the product after more than 5 years.

I hope people who have difficulty starting or continuing salt reduction will use Electric Salt as a tool to enjoy a wide range of meals and enrich their dietary life.

Future development of "Electric Salt"
Kirin will continue to propose the development of tableware other than spoons and low-sodium food menus, and we will work with companies and local governments to expand the use of Electric Salt and its market. Electric Salt aims to provide services that enable consumers to enjoy eating healthy, delicious, and enjoyable foods and to realize a healthy and happy society.

About Kirin Holdings
(Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.
Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.
Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become “A global leader in CSV*, creating value across our world of Food & Beverages to Pharmaceuticals.” Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.
*: Creating Shared Value. Combined added value for consumers as well as for society at large.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240519949395/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye